Discovery Could Bring New Metastatic Cancer Treatments

	Tweet

Virginia Commonwealth University and VCU Massey Cancer Center researchers have uncovered how a gene, melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24), induces a bystander effect that kills cancer cells not directly receiving mda-7/IL-24 without harming healthy ones, a discovery that could lead to new therapeutic strategies to fight metastatic disease.

The findings may provide a method to target metastatic disease – which is one of the primary challenges in cancer therapy. When cancer cells are localized in the body, specialists may be able to surgically remove the diseased area. However, when cancer metastasizes or spreads to sites remote from the primary tumor through the lymph system and blood vessels to new target sites, treatment becomes more difficult and in many instances ineffective.

In the study, published online in the June 30 issue of the Proceedings of the National Academy of Sciences, researchers report on the molecular and biochemical mechanisms by which the gene, mda-7/IL-24, is able to selectively kill cancer cells through apoptosis, or programmed cell death. The gene induces a potent bystander effect, meaning that it not only kills the original tumor, but distant ones as well, which has been observed but previously not mechanistically defined in animal models containing human cancers and in a Phase I Clinical Trial involving direct injection of an adenovirus expressing mda-7/IL-24 into advanced carcinomas and melanomas.

Further, the team determined that mda-7/IL-24 induces tumor-specific killing through a process known as endoplasmic reticulum stress. The endoplasmic reticulum, or ER, is a subcellular structure that plays a key role in cellular protein disposition. ER stress results from accumulation of extra proteins in the ER of a cancer cell and can activate pro-survival or pro-cell suicide pathways.

“Cancer cells cannot accommodate or recover from stress the way normal, healthy cells can. When the ER is stressed in this way, the result is an unfolded protein response which overloads the system and shorts out the cancer cell. This prevents tumor development, growth and invasion – and ultimately the cancer cell dies,” said Paul B. Fisher, Ph.D., professor and interim chair of the Department of Human and Molecular Genetics, and director of the VCU Institute of Molecular Medicine, in the VCU School of Medicine.

This work was supported by grants from the National Institutes of Health and the Samuel Waxman Cancer Research Foundation.

In related work, Fisher, who is the first incumbent of the Thelma Newmeyer Corman Endowed Chair in Cancer Research and researcher with the VCU Massey Cancer Center, has been invited by the NIH’s National Cancer Institute to present his team’s translational research on mda-7/IL-24 at the National Cancer Institute’s (NCI) Translational Science Meeting. The research focuses on using mda-7/IL-24 in the development of therapies for prostate cancer, malignant glioma and ovarian cancer. The meeting is scheduled for November 2008 in Washington, D.C.

Fisher worked with a team that included VCU School of Medicine researchers Paul Dent, Ph.D., professor in the VCU Department of Biochemistry and Molecular Biology; Zaozhong Su, Ph.D., associate professor in the VCU Department of Human and Molecular Genetics; Devanand Sarkar, Ph.D., assistant professor at the VCU Massey Cancer Center and Department of Human and Molecular Genetics; and Moira Sauane, Ph.D.; Pankaj Gupta, Ph.D.; and Irina V. Lebedeva, Ph.D., with the Columbia University College of Physicians and Surgeons in New York.

EDITOR’S NOTE: A copy of the study is available for reporters by email request from .

Source: Virginia Commonwealth University

RELATED STORIES:
Cancer patients often forget details of doctor visit   Nicotine interferes with chemotherapy, study finds   Normalizing Tumor Vessels to Improve Cancer Therapy   Diet and cancer prevention: New evidence for the protective effects of fruits and veggies   Therapeutic gene suspected to cause cancer   Deactivating a cancer growth promoter   Radiation after surgery reduces chance of melanoma returning   Individual mutations are very slow to promote tumor growth   Multikine treatment increases survival in cancer patients   Reovirus could be used to treat many forms of advanced cancer   Biomarker Test Shows Promise for Melanoma Diagnosis   Washington University Scientists First to Sequence Genome of Cancer Patient   Genes that both extend life and protect against cancer identified   March is National Professional Social Work Month   Selenium doesn’t prevent cancer: report   PCB exposure may raise lymphoma risk   29% of Cancer Studies Report Conflict of Interest   ‘Chemical Nose’ May Sniff Out Cancer Earlier   Women underrepresented in most cancer research   Medical Society’s Labor Day CheckList Addresses Cancer Prevention   Chemotherapy Complications Greater than Previously Estimated   Why are blacks more likely to die from cancer diagnosis?

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]